Showing results (1-10 of 14) with videos related to
Sort By:
Pageof 2
The Journal of Surgical Research|June 2, 2009
Preoperative thyroid ultrasound in all patients undergoing parathyroidectomy?Jeremy D Gates, Linda C Benavides, Craig D Shriver, et al.Cancer|November 20, 2009
Results of the first phase 1 clinical trial of the HER-2/neu peptide (GP2) vaccine in disease-free breast cancer patients: United States Military Cancer Institute Clinical Trials Group Study I-04Mark G Carmichael, Linda C Benavides, Jarrod P Holmes, et al.Cancer|September 17, 2010
Use of booster inoculations to sustain the clinical effect of an adjuvant breast cancer vaccine: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02Jarrod P Holmes, Guy T Clifton, Ritesh Patil, et al.Journal of the American College of Surgeons|February 2, 2010
Clinical and immunologic responses of HLA-A3+ breast cancer patients vaccinated with the HER2/neu-derived peptide vaccine, E75, in a phase I/II clinical trialRitesh Patil, Guy T Clifton, Jarrod P Holmes, et al.Journal of Cancer|January 3, 2012
Preoperative thyroid ultrasound is indicated in patients undergoing parathyroidectomy for primary hyperparathyroidismCletus A Arciero, Zita S Shiue, Jeremy D Gates, et al.Cancer|August 30, 2008
Optimal dose and schedule of an HER-2/neu (E75) peptide vaccine to prevent breast cancer recurrence: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02Jarrod P Holmes, Jeremy D Gates, Linda C Benavides, et al.Expert Review of Vaccines|February 22, 2011
Comparison of different HER2/neu vaccines in adjuvant breast cancer trials: implications for dosing of peptide vaccinesLinda C Benavides, Alan K Sears, Jeremy D Gates, et al.Cancer|October 13, 2011
Clinical trial results of the HER-2/neu (E75) vaccine to prevent breast cancer recurrence in high-risk patients: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02Elizabeth A Mittendorf, Guy T Clifton, Jarrod P Holmes, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 9, 2009
The impact of HER2/neu expression level on response to the E75 vaccine: from U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02Linda C Benavides, Jeremy D Gates, Mark G Carmichael, et al.Journal of the American College of Surgeons|February 21, 2009
Longterm followup assessment of a HER2/neu peptide (E75) vaccine for prevention of recurrence in high-risk prostate cancer patientsJeremy D Gates, Mark G Carmichael, Linda C Benavides, et al.Pageof 2